Previous close | 206.15 |
Open | 206.34 |
Bid | 207.20 x 1100 |
Ask | 207.37 x 800 |
Day's range | 205.46 - 207.80 |
52-week range | 179.59 - 234.09 |
Volume | |
Avg. volume | 807,753 |
Market cap | 17.505B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | 44.47 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.39%) |
Ex-dividend date | 28 May 2024 |
1y target est | N/A |
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website. An archived replay of the webcast will be available for one year.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company, announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.